Wegovy's Real-World weight loss power tested in 500 korean patients
NCT ID NCT07280221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 500 Korean adults with obesity who are starting Wegovy (semaglutide) as part of their normal care. Researchers will track how much weight they lose and any side effects over about 52 weeks. The goal is to see how effective and safe the drug is in real-world clinics, not a controlled research setting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Daejeon Endo Internal Medicine Clinic
Daejeon, 35220, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?